An evaluation of the efficacy and value of CVT-301 for the treatment of Parkinson’s disease

References

• Jankovic J. Levodopa strengths and weaknesses. Neurology. 2002;58(suppl 1):S19–S32.
   PubMed Web of Science ®Google Scholar
• LeWitt PA. Levodopa for the treatment of Parkinson’s disease. N Engl J Med. 2008;359:2468–2476.
   PubMed Web of Science ®Google Scholar
• Zappia M, Oliveri RL, Montesanti R, et al. Loss of long-duration response to levodopa over time in PD: implications for wearing-off. Neurology. 1999 Mar 10;52(4):763–767.
   PubMed Web of Science ®Google Scholar
• Chase TN, Baronti F, Fabbrini G, et al. Rationale for continuous dopaminomimetic therapy of Parkinson’s disease. Neurology. 1989 Nov;39(11Suppl 2):7–10. discussion 19. PMID: 2685653.
   PubMed Web of Science ®Google Scholar
• Stocchi F. The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson’s disease. Parkinsonism Relat Disord. 2009 Dec;15(Suppl 3):S68–71.
   PubMedGoogle Scholar
• Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Drugs. 1998;55(Suppl 1):1–9.
   PubMed Web of Science ®Google Scholar
• Nyholm H, Lennernas H. Irregular gastrointestinal drug absorption in Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2008;4:193–203.
   PubMed Web of Science ®Google Scholar
• Müller T, Erdmann C, Bremen D, et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol. 2006;29:61–67.
   PubMed Web of Science ®Google Scholar
• Crevoisier C, Zerr P, Calvi-Gries F, et al. Effects of food on the pharmacokinetics of levodopa in a dual-release formulation. Eur J Pharm Biopharm. 2003;55:71–76.
   PubMed Web of Science ®Google Scholar
• Thanvi BR, Lo TCN. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad Med J. 2004;80:452–458.
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–2508.
   PubMed Web of Science ®Google Scholar
• Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol. 2005;252(Suppl.4):37–42. IV.
   Google Scholar
• Stocchi F, Antonini A, Barone P, et al., Early DEtection of wEaring off in Parkinson disease: the DEEP study. Parkinsonism Relat Disord. 20(2): 204–211. 2014.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord. 2005;11:11–16.
   Web of Science ®Google Scholar
• Chou KL, Stacy M, Simuni T, et al. The spectrum of “off” in Parkinson’s disease: what have we learned over 40 years? Parkinsonism Relat Disord. 2018;51:9–16.
   PubMed Web of Science ®Google Scholar
• Adler CH. Relevance of motor complications in Parkinson’s disease. Neurology. 2002;58(4 Suppl 1):S51–S56.
   PubMed Web of Science ®Google Scholar
• Olanow CW. Stocchi F Levodopa: a new look at an old friend. Mov Disord. 2017 Nov 27. 10.1002/mds.27216.
   Web of Science ®Google Scholar
• Stocchi F, Tagliati M, Olanow CW. Treatment of levodopa-induced motor complications. Mov Disord. 2008;23(Suppl 3):S599–612.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Ondo WG, Van Lunen B, et al. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating “off” episodes in advanced Parkinson disease. Clin Neuropharmacol. 2009;32:89–93.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Chaudhuri KR, LeWitt P, et al. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses. Clin Neuropharmacol. 2015;38:89–103.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Olanow CW, Dzyngel B, et al. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson’s disease. Mov Disord. 2016;31(9):1366–1372.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Factor SA, Espay AJ, et al. Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020;19(2):135‐144.
   PubMed Web of Science ®Google Scholar
• Bartus RT, Emerich D, Snodgrass-Belt P, et al. A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson’s disease. J Pharmacol Exp Ther. 2004;310:828–835.
   PubMed Web of Science ®Google Scholar
• Freed MI, Batycky R, Merica E. Safety, tolerability, and pharmacokinetics following inhaled administration of CVT-301, a levodopa powder aerosol, in healthy adult subjects [abstract]. Mov Disord. 2013;28(Suppl 1):430.
   Google Scholar
• DeLong M, Wright J, Dawson M, et al. Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates. J Aerosol Med. 2005;18:452–459.
   PubMedGoogle Scholar
• Rave K, De La Pena A, Tibaldi FS, et al. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. Diabetes Care. 2007;30:1777.
   PubMed Web of Science ®Google Scholar
• Healy AM, Amaro MI, Paluch KJ, et al. Dry powders for oral inhalation free of lactose carrier particles, Adv. Drug Deliv Rev. 2014;8:32–35.
   Web of Science ®Google Scholar
• Lipp MM, Batycky R, Moore J, et al. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson’s disease. Sci Transl Med. 2016 Oct 12;8:360ra136.
   PubMed Web of Science ®Google Scholar
• Safirstein BE, Ellenbogen A, Zhao P, et al. Pharmacokinetics of inhaled levodopa administered with oral Carbidopa in the Fed State in patients with Parkinson’s disease. Clin Ther. Clin Ther. 2020 Jun;42(6):1034–1046.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Vacca L, Stirpe P, et al. Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1189–1195.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Hauser RA, Grosset DG, et al. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson’s disease. Mov Disord. 2016 Sep;31(9):1356–1365.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Hauser RA, Pahwa R, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial [published correction appears in Lancet Neurol. Lancet Neurol. 2019;18(2):145‐154. 2019 Mar;18(3):e2.
   PubMed Web of Science ®Google Scholar
• Grosset DG, Dhall R, Gurevich T, et al. Inhaled levodopa in Parkinson’s disease patients with OFF periods: a randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2020;71:4‐10.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Pahwa R, Sedkov A, et al. Pulmonary safety and tolerability of inhaled levodopa (CVT-301) administered to patients with Parkinson’s disease. J Aerosol Med Pulm Drug Deliv. 2018 Jun;31(3):155–161.
   PubMed Web of Science ®Google Scholar
• Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179–187.
   PubMed Web of Science ®Google Scholar
• Sabate M, Gonz_alez I, Ruperez F, et al. Obstructive and restrictive pulmonary dysfunctions in Parkinson’s disease. J Neurol. Sci1996(138):114–119.
   Google Scholar
• Hauser RA, Isaacson SH, Ellenbogen A, et al. Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson’s disease. Parkinsonism Relat Disord. 2019;64:175‐180.
   PubMed Web of Science ®Google Scholar
• Luinstra M, Grasmeijer F, Hagedoorn P, et al. A levodopa dry powder inhaler for the treatment of Parkinson’s disease patients in off periods. Eur J Pharm Biopharm. 2015;97:22–29.
   PubMed Web of Science ®Google Scholar
• Luinstra M, Isufi V, De Jong L, et al. Learning from Parkinson’s patients: usability of the Cyclops dry powder inhaler. Int J Pharm. 2019 Aug;15(567):118493.
   Web of Science ®Google Scholar